ImmunityBio Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

ImmunityBio şirketinin kazançları yıllık ortalama -18% oranında azalırken, Biotechs sektörünün kazançları yıllık 15.2% oranında artan oldu. Gelirler yıllık ortalama 136.3% oranında artan oldu.

Anahtar bilgiler

-18.05%

Kazanç büyüme oranı

-4.46%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.04%
Gelir büyüme oranı	136.26%
Özkaynak getirisi	n/a
Net Marj	-1,310.30%
Son Kazanç Güncellemesi	31 Mar 2025

Yakın geçmiş performans güncellemeleri

Recent updates

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 07

Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Mar 06

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

Dec 11

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

Oct 25

ImmunityBio: Moving The Needle

Oct 07

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 21

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 14

Gelir ve Gider Dağılımı

ImmunityBio nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:IBRX Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 25	31	-409	164	180
31 Dec 24	15	-414	173	186
30 Sep 24	7	-588	165	202
30 Jun 24	1	-598	161	200
31 Mar 24	0	-601	144	201
31 Dec 23	1	-583	135	227
30 Sep 23	1	-458	129	232
30 Jun 23	1	-473	117	256
31 Mar 23	1	-430	101	266
31 Dec 22	0	-417	109	242
30 Sep 22	1	-400	93	241
30 Jun 22	1	-376	103	218
31 Mar 22	1	-370	119	209
31 Dec 21	1	-347	127	192
30 Sep 21	0	-323	124	186
30 Jun 21	0	-301	112	174
31 Mar 21	1	-264	97	154
31 Dec 20	1	-222	61	140
30 Sep 20	2	-176	56	110
31 Dec 19	2	-158	46	112
31 Dec 18	3	-84	29	47

Kaliteli Kazançlar: IBRX şu anda kârlı değil.

Büyüyen Kar Marjı: IBRX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IBRX kârlı değildir ve zararlar son 5 yılda yılda 18% oranında artmıştır.

Büyüme Hızlandırma: IBRX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: IBRX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 21.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: IBRX 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/30 18:44
Gün Sonu Hisse Fiyatı	2025/05/30 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ImmunityBio, Inc. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Justin Zelin	BTIG
Jason Kolbert	D. Boral Capital LLC.
Andres Maldonado	H.C. Wainwright & Co.

ImmunityBio Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2025 earnings: EPS misses analyst expectations

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

First quarter 2025 earnings: EPS misses analyst expectations

ImmunityBio, Inc. Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Supplemental Biologics License Application

ImmunityBio, Inc., Annual General Meeting, Jun 18, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

ImmunityBio, Inc. Announces Positive Long-Term Results from Its Quilt-3.032 Study of Anktiva® (Nogapendekin Alfa Inbakicept-Guerin) Plus BCG

New major risk - Shareholder dilution

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $75.000001 million.

Pomerantz LLP and Holzer & Holzer, LLC Announces Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio, Inc. Announces First Dosing of Recombinant BCG in the U.S. and 60 Sites Are in the Process of Launching

Consensus revenue estimates decrease by 23%, EPS upgraded

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Price target decreased by 7.7% to US$11.25

Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

New minor risk - Shareholder dilution

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ImmunityBio, Inc. Announces Certain Operational Results Following Approval of the Permanent J-Code (J9028) in January 2025

New major risk - Share price stability

ImmunityBio, Inc. Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-Of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

President exercised options and sold US$267k worth of stock

U.S. Food and Drug Administration Authorizes ImmunityBio, Inc. to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

Immunitybio, Inc. Announces Uk Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for Anktiva

John Owen Brennan Resigns as a Member of the Board of Directors and from All Committees of the Board of ImmunityBio, Inc

ImmunityBio, Inc. Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA®? for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio, Inc. Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Immunitybio, Inc. Announces Permanent J-Code (J9028) for Anktiva®? Is Now Effective

Forecast to breakeven in 2027

ImmunityBio, Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

New major risk - Share price stability

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

ImmunityBio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates fall by 15%

ImmunityBio, Inc. Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS

Consensus revenue estimates increase by 177%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

ImmunityBio, Inc. Announces First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

ImmunityBio: Moving The Needle

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Consensus revenue estimates fall by 86%

Consensus EPS estimates fall by 18%

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

ImmunityBio, Inc.'s ANKTIVA® Now Covered by More Than a Dozen Insurance Plans Representing over 100 Million Lives Within Months of FDA Approval

ImmunityBio, Inc Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio: All Eyes On Execution Now (Rating Upgrade)

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

ImmunityBio: Anktiva's Launch Demands A Reassessment

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Consensus revenue estimates increase by 639%, EPS downgraded

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle

Insufficient new directors

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise

New major risk - Share price stability

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

ImmunityBio: Buy Low Now Vs. Buy High Later